Orchestra BioMed Holdings, Inc.
OBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $0 |
| % Growth | 3% | -3.7% | 243.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $1 | $0 |
| % Margin | 94.3% | 94.5% | 94.9% | 77.1% |
| R&D Expenses | $14 | $14 | $13 | $11 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $7 | $6 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $21 | $20 | $20 | $17 |
| Operating Income | -$20 | -$19 | -$19 | -$17 |
| % Margin | -2,359.2% | -2,311.8% | -2,179.8% | -6,591.7% |
| Other Income/Exp. Net | -$1 | -$0 | $0 | $1 |
| Pre-Tax Income | -$21 | -$19 | -$19 | -$16 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$21 | -$19 | -$19 | -$16 |
| % Margin | -2,419% | -2,316.1% | -2,160.7% | -6,385.4% |
| EPS | -0.4 | -0.5 | -0.49 | -0.42 |
| % Growth | 20% | -2% | -16.7% | – |
| EPS Diluted | -0.4 | -0.5 | -0.49 | -0.42 |
| Weighted Avg Shares Out | 38 | 38 | 38 | 38 |
| Weighted Avg Shares Out Dil | 38 | 38 | 38 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$20 | -$19 | -$19 | -$17 |
| % Margin | -2,349.8% | -2,302.2% | -2,151.2% | -6,558.5% |